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PREFACE 
The purpose of this study was to develop a metabolic 
activation system for the Frog Embryo Teratogenesis 
Assay: Xenopus (FETAX). Metabolism is a significant 
obstacle for most in vitro developmental toxicity assays 
and must not be overlooked in a proper screening test. 
Such a system when incorporated into the FETAX protocol 
will help eliminate potential false negative and false 
positive test results. In addition, it will provide 
meaningful insight into the effect of maternal metabolism 
on the developmental toxicity of compounds in the 
environment and workplace. 
This thesis is divided into four chapters. An 
introduction to this work is presented in Chapter I, with 
a review of pertinent literature in Chapter II. Chapter 
III is a complete manuscript prepared and submitted for 
publication to the journal, Teratogenesis, Carcinogenesis, 
and Mutagenesis. The development of a metabolic 
activation system consisting of Aroclor 1254 induced rat 
liver microsomes is presented in Chapter III. Chapter 
IV describes preliminary validation of the metabolic 
activation system. 
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indebted to Debbie 1. Newell and Brenda Ben James for 
their technical support. Dr. Greg Smith provided 
excellent assistance and advice on the gas chromatograph. 
Greg was most helpful throughout the study and participated 
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CHAPTER I 
INTRODUCTION 
Statement of Problem 
Approximately 70,000-90,000 chemicals are currently 
available in the marketplace with some 600 new chemicals 
released each year. Prior to their release into the 
marketplace and ultimately the environment, the safety 
of these chemicals must be firmly established. The 
Environmental Protection Agency (EPA), under the Toxic 
Substance Control Act (TOSCA) and the Federal Insecticide, 
Fungicide, and Rodenticide Act (FIFRA), has regulatory 
responsibility for the majority of these chemicals. 
Because of the large number of interactions possible when 
these chemicals are present in complex mixtures, in vivo 
assays employing mammals are not practical. Changing 
perceptions among the scientific, regulatory, and 
industrial communities on the issue of alternate methods 
were recently documented by the EPA's Office of Policy, 
Planning, and Evaluation (1). Of interest to the 
proposed study, the need for routine teratogenicity 
testing has led to the development of a number of in 
vitro teratogenesis assays that may prove useful in 
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prioritizing compounds for further testing (2-7). The 
use of the in vitro systems was identified in 
developmental effects test guidelines published by the 
EPA (8). In 1983, Dumont and coworkers (9) developed the 
Frog Embryo Teratogenesis Assay: Xenopus (FETAX) and 
applied it to screening complex environmental mixtures 
as well as pure compounds. However, early Xenopus 
embryos do not have a functioning mixed-functional 
oxidase system (MFO). Many compounds that require 
metabolic activation in order to be teratogenic would 
presently be falsely scored as negative in the FETAX. 
Compounds that are deactivated by the MFO would be· 
incorrectly scored as positives. The most straightforward 
approach to solving this deficiency is to provide an 
exogenous metabolic activation system (MAS). Once 
provided, the utility of the assay must be established 
with appropriate validation compounds. The purpose of 
this study was to develop a metabolic activation system 
for FETAX using Aroclor 1254 induced rat liver 
microsomes. This system when routinely used with FETAX 
may reduce the number of false positive and negative 
test results. 
Objectives 
FETAX presently meets most of the criteria set forth 
by Kimmel et al. (10) for in vitro teratogenesis assay 
validation (9,11,12). Mortality, malformation, and 
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growth endpoints are easily quantifiable, generally 
exhibiting a dose-response relationship with the 
development of narrow confidence limits. Since many of 
the stages of the amphibian development are similar to 
mammalian development, the "developmental relevance" of 
FETAX is more significant (13) than many of the other 
teratogenesis assays available. Presently, FETAX lacks a 
MAS. Without such a system, it is doubtful that FETAX 
would be commonly used by research laboratories or 
approved for use by regulatory agencies. Because of 
this, an effective and efficient in vitro MAS will be 
developed using Aroclor 1254 induced rat.liver 
microsomes. 
Metabolic Incompetence 
A recognized obstacle in most in vitro assay systems 
is the inability to biotransform compounds into active 
teratogenic species. Metabolism must not be overlooked 
in a proper screening test (10). Furthermore, compounds 
should be tested both with and without a metabolic 
activating system, exogenous when necessary. 
Obviously, some metabolic activation systems are 
incompatible with the viability of the test. Of those 
tests supplying a source of metabolism, the Ames 
mutagenicity test (22) and a cultured whole rat embryo 
screen (23) employ rat liver S-9 supernatant. Drosophila 
have been successfully cultured with both Drosophila and 
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rat liver S-27 and S-9 supernatant (24). In addition, 
cultured mouse erythrocytes have been used to mediate the 
the metabolic activation of cyclophosphamide in the 
Saccharomyces cerevisiae mutagenicity test (25). 
Noshiro and Omura (26) demonstrated that Xenopus 
embryos exhibit little xenobiotic metabolism although the 
adult has limited capabilities. Therefore, through 96 h 
of development Xenopus embryos are virtually useless for 
detecting proteratogenic compounds without an exogenous 
metabolic activation system. 
Experimental Design 
Detection of Teratogenic Agents Using 
Xenopus Embryos 
The original study on a bioassay employing Xenopus 
to detect environmental teratogens was performed by 
Greenhouse (7). Greenhouse used a short-term (48-hour) 
protocol exposing embryos to N-phenyl-a-napthylamine and 
various hydrazines to demonstrate the deleterious effects 
on developing embryos. Dumont et al. (14) demonstrated 
the hazardous effects of coal-conversion, shale and oil 
products on Xenopus embryos using a 96 h exposure 
protocol. 
In order to measure the teratogenic potential of a 
substance, Xenopus embryos in the late blastulae stage 
were exposed to different concentrations of a toxicant. 
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Mortality, malformation, and growth were measured at the 
end of the 4 day test. As a measure of predicting the 
teratogenic risk of a given substance, a teratogenicity 
index (TI) was calculated by dividing the 96 h LC50 
(median lethal concentration) by the EC50 (malformation) 
(median teratogenic concentration) (14). Compounds with 
TI values greater than 1.5 are considered to have strong 
teratogenic potential. Subsequently, several labora-
tories (11,12,13) have used FETAX for the screening of 
potential developmental toxicants. 
Design of the Metabolic Activation 
System 
Rat liver microsomes were isolated from adult male 
Sprague-Dawley rats treated with 500 mg/kg Aroclor 1254 
according to a modified procedure of Kitchin and Woods 
(15). Following isolation, purified microsome aliquots 
were immediately frozen in liquid nitrogen (16). Protein 
was determined by the method of Bradford (17). P-450 
activity was inferred by the formaldehyde generated from 
the N-demethylation of aminopyrine by the method of Nash 
(18). Assay conditions were described by Lucier et al. 
(19). Several aliquots of microsomes were pretreated 
with carbon monoxide (CO) to selectively inactivate 
cytochrome P-450 (P-450) activity. 
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Incorporation into FETAX Protocol 
Initial tests were conducted to determine the most 
suitable concentration of microsomal protein, NADPH 
generating system, and antibiotics using sublethal and 
subteratogenic concentrations of cyclophosphamide. For 
each clutch of embryos, four sets of 20 embryos were 
exposed to reconstituted water (FETAX solution) (20) and 
penicillin-streptomycin. These were designated FETAX 
controls. Treatments were performed in duplicate with 20 
embryos per dish. Each test dish received microsomal 
protein, NADPH generating system, penicillin-
streptomycin, and various concentrations of toxicant. 
Metabolic activation system, unactivated toxicant, and 
CO-gassed MAS controls plus toxicant were performed in 
addition. All solutions were removed every 24 hours of 
the test and new solutions added in a static-renewal 
fashion. The number of live-malformed embryos at 96 
hours and the stage of development according to 
Nieuwkoop and Faber (21) were determined. Dose-response 
assays evaluated according to Litchfield-Wilcoxon were 
used to determine the 96 hour LC50 and EC50 (malformation). 
The head-tail length was then measured as an additional 
endpoint. 
The Use of Cyclophosphamide 
Cyclophosphamide is a consensus compound listed 
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by Smith et al. (13) for use in validating in vitro 
teratogenesis assays. In vitro rodent embryo culture has 
demonstrated that cyclophosphamide must be bioactivated 
to be teratogenic (23,27). The metabolism of 
cyclophosphamide, mutagenic effects, and teratogenic 
potential have been thoroughly investigated, making it an 
excellent compound for the development of such a system. 
In addition, cyclophosphamide is soluble in water, thus 
eliminating the need for a carrier solvent. 
Alternate Metabolic Activation Systems 
Cultured Hepatocytes 
One alternative is the use of Xenopus hepatocytes in 
a coculture with Xenopus embryos. One advantage of 
using cultured hepatocytes as a metabolic activation 
system would be the continuous production of the active 
metabolite. However, Xenopus hepatocytes have far less 
inducible P-450 than do rat liver microsomes, while rat 
liver microsomes have a similar basal level of P-450 
activity to human (28). Rat liver hepatocytes cannot be 
used because o£ the osmotic differences between 
amphibian and mammalian cells. Cell culture is far more 
expensive and technically difficult than the use of rat 
liver microsomes. Furthermore, there are problems with 
plating the exact number of hepatocytes so that 
bioactivation is consistent and the test is repeatable. 
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Whole-Liver Perfusion 
Isolated adult Xenopus liver perfusion has also been 
considered as a possible method of converting 
proteratogens to teratogens. The perfusate containing 
the active metabolites would flow through culture dishes 
containing developing embryos. Again, an advantage of 
using liver perfusion would be the continuous generation 
of the active metabolite. The limited amount of Xenopus 
P-450 poses a significant disadvantage. This system is 
significantly more complex and expensive than an in vitro 
rat liver microsome/embryo coculture system. Inducing 
Xenopus liver P-450 with Aroclor 1254 offers no advantage, 
as reducing residual Aroclor 1254 exposed to the 
developing embryos would be technically difficult. 
Obviously, every in vitro metabolic activation system has 
advantages and disadvantages and no system has been 
universally accepted that simulates human metabolism. 
However, a metabolic activation system employing Aroclor 
1254 induced rat liver microsomes appears to be the most 
straightforward approach. Implementing such a system 
into the FETAX protocol will increase the predictive 
value of the assay and increase the overall acceptance 
of FETAX as developmental toxicity screen. 
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CHAPTER II 
LITERATURE REVIEW 
In Vitro Teratogenicity Testing 
Aspects of Successful In Vitro Assays 
Measurement £f Teratogenic Potential. It has become 
recently apparent that the current in vivo test 
procedures are overburdened by the large number of 
compounds requiring testing. Such a predicament has 
given rise to the development of short-term 
teratogenicity screens. To be successful, short-term in 
vitro screens must mimic the widely accepted in vivo 
mammalian developmental toxicity tests. However, until 
recently methods for validating in vitro systems were 
undefined. Obviously several questions must be 
considered (see 10 for a review). First, what is an 
acceptable measure of teratogenic potential for in vitro 
test systems? Obviously, an acceptable measure of 
teratogenic potential in vitro is an endpoint that would 
predict findings of generally accepted evaluations of 
teratogenic potential in vivo. 
Second, should these endpoints be related to 
embryogenic events that occur in the intact mammalian 
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system? In this case, the endpoints need not necessarily 
be related to embryogenic events, although an ontogenic 
system is desirable. Eventually all in vitro screens 
should predict human teratogenicity. The wide variety of 
in vitro developmental toxicity screens and the equally 
large number of endpoints used to assess potential risk 
makes evaluation difficult. For example, cell culture 
systems measure endpoints far removed from malformation 
and functional deformities. Rather, it measures an event 
that may or may not be relevant to the production of 
malformations. 
Approaches. If a single test is to be used as a sole 
indicator of teratogenic risk, the degree of 
developmental relevance to mammals must be great. Of 
those tests which bear little relevance to ontogeny, a 
battery of short-term assays are generally performed to 
form a composite answer. The battery approach is 
considered superior to the tier strategy (55). In the 
tier system, compounds initially are tested with 
inexpensive short-term tests. Those chemicals which test 
positive are then subjected to more rigorous testing. 
Since false negatives may occur during the initial 
screening, the possibility that a teratogen will evade 
detection is greater. 
Assay Validation. In order to establish in vitro 
systems as an acceptable screening process, extensive vali-
dation must be performed. Generally compounds should be 
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selected on the basis of their ~ vivo teratogenic 
activity from a list of agents selected by a panel of 
experienced investigators in the areas of teratology, 
pharmacokinetics, metabolism, and chemical 
classification. Validation in this manner facilitates 
interlaboratory comparisons. An overabudance of false-
positive and negative test results detract from the 
validity of the test, depending on its use as part of a 
test battery or a single test, and its level in the 
overall toxicity assessment process. 
Performance and Developmental 
Relevance of FETAX 
Test performance and developmental relevance make 
FETAX an attractive in vitro teratogenesis bioassay. Of 
32 compounds tested with FETAX, 85 percent were similar 
to mammalian studies (56-57). Sabourin and Falk (58) have 
recently found that the total mammalian malformation 
(e.g., skeletal, visceral, nervous, etc.) caused by 17 
teratogens were matched in Xenopus in 24/37 (65%) of the 
cases. The correlation between laboratories using FETAX 
indicates much promise for the assay as well. Courchesne 
and Bantle (11) found the teratogenic index of hydroxyurea 
to be 4.3 which is very similar to 4.5 obtained by 
Sabourin et al. (12). However, this was not always the 
situation, as was the case with 5-fluorouracil which 
tested strongly teratogenic in the laboratories of both 
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Bantle and Sabourin, but the teratogenicity index varied 
significantly. FETAX (12) was found to be the most 
appropriate assay when compared to the Planaria (3) and 
the Hydra system (59). These results may be attributed 
to the multiple endpoints of the frog assay as well as 
its higher phylogenetic position. Dumont et al. (9) 
found meclizine induced hydrocephalia in both frogs and 
mammals. Courchesne and Bantle (11) found that several 
genotoxic compounds caused the same general malformations 
in both Xenopus and rodent embryos. In addition, 
anomalies produced by ethanol, caffeine, and 5-
fluorouracil exposure were similar to those reco~ded in 
mammalian studies (20). 
The Role of P-450 in Xenobiotic 
Metabolism 
Importance of Xenobiotic Metabolism 
Living organisms are exposed to a wide variety of 
substances, some necessary for the maintenance of life, 
some of medicinal value, and others of no functional 
value. The latter two classes are commonly called 
xenobiotics, or those compounds which are foreign to an 
organism. Whether a compound is a xenobiotic or not is 
species dependent since a compound which is foreign for 
one species may be essential for another. Anstrom and 
DePierre (29) suggest that xenobiotics have been present 
12 
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on earth for 10 years, formed either by natural 
processes or, more recently and ever increasing, by waste 
products of civilization. 
Organisms may handle the problem of exposure to 
xenobiotics by two fundamental methods: either by 
preventing them from entering the body, and/or excreting 
them rapidly (29). Since highly evolved biological 
membranes provide no permeability barrier for hydrophobic 
compounds and since the vast majority of xenobiotics are 
hydrophobic, the evolution of systems for excretion has 
been fundamental to life. Water-soluble (lipophobic) 
chemicals may be easily excreted throu~h the urine and 
bile. Lipid-soluble (lipophilic) substances are often 
excreted slowly and tend to remain in the body for long 
periods of time. This facilitates accumulation to 
potentially toxic concentrations. Therefore, the major 
goal of xenobiotic metabolism is to render lipophilic 
compounds more water-soluble so that they may more 
readily be excreted. 
Since xenobiotics often have no structurally similar 
endogenous counterparts, unlike many pharmaceutical 
agents, the evolution of unspecific xenobiotic 
biotransforming enzymes was necessary. Consistent with 
the evolutionary trend of organ specialization, the 
highest activities of drug-metabolizing enzymes is found 
in the liver. 
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The P-450 System 
Xenobiotic metabolism can be generally divided into 
three steps: 1) activation of the compound; 2) inactivation 
(usually) of reactive groups by hydrolysis or conjugation 
with glutathione; and 3) conjugation with other 
hydrophilic moieties, such as glucuronic acid, sulfate, 
or acetate to make the compound more water-soluble (29). 
P-450 is involved in the first process called phase I 
metabolism. The latter conjugation steps are designated 
as phase II processes. 
The P-450 system, also known as the mixed-functional 
oxidase system (MFO), has been found in different levels 
and forms in virtually all species (30-32). Within the 
cell, P-450 activity is chiefly located on the 
endoplasmic reticulum (30-32) but has been found in the 
nuclear membrane (33,34), and mitochondria (32,35). 
This system in microsomes consists of two proteins: the 
flavoprotein NADPH-P-450 reductase which reduces P-450 by 
a two electron transfer mechanism and cytochrome b 
5 
(36,37). The second electron may be transfered from 
cytochrome b (38-41). P-450 usually catalyzes the 
5 
insertion of one oxygen atom from molecular oxygen into 
the substrate, while the other is used in the formation 
of water. P-450 when reduced and bound to carbon 
monoxide exhibits a difference spectrum with a 
characteristic maximum at approximately 450 om (42). 
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The broad substrate specificity of P-450 gives rise 
to numerous phase I reactions, including aromatic and 
aliphatic hydroxylation, epoxidation, N-demethylation, 
0-dealkylation, and Nand S-oxidation (43). It should also 
be mentioned that P-450 is involved in the metabolism of 
several endogenous substrates, most notably steroids, 
fatty acids, and prostaglandins (44-47). 
Bioactivation 
The metabolism of xenobiotics is not always a one-
way street. Often the system gives rise to products more 
toxic than the parent compounds in the process. Reactive 
nucleophilic products formed during drug metabolism can 
react with electrophilic groups in the cell, usually 
localized in proteins, RNA and DNA (29). Such reactions 
may give rise to toxic and/or genotoxic effects, such as 
mutagenesis, carcinogenesis, and teratogenesis. 
Induction of P-450 Isozymes 
The Effect of Inducing Agents 
In essense, ten major cytochrome P-450 isozymes from 
rat liver microsomes have been isolated and designated 
P-450a through P-450j (28). Immunochemical quantification 
of hepatic microsomes from rats treated with three 
inducers such as phenobarbital (PB), 3-methylcholanthrene 
(3-MC), and Aroclor 1254 (mixture of polychlorinated 
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biphenyls) have been recently studied (48-52). A 4-day 
treatment of rats with PB caused a 39-fold increase in 
P-450b and a doubling of P-450a with no change observed in 
the other isozymes. Treatment of rats with 3-MC caused a 
71- to 74-fold increase in the amount of P-450c, a 10 fold 
increase in P-450d, and a 3- to 4-fold increase in P-450a, 
with no change in the other isozymes. Treatment of rats 
with Aroclor 1254 caused a 44 to 49 fold increase in the 
concentrations of P-450b and P-450c, a 19 fold increase 
in P-450d, and a 3 fold increase in P-450a. Although 
Aroclor 1254 greatly increases the quantity of several 
cytochrome P-450 isozymes, a few other isozymes may be 
repressed (50,51). 
Types of Inducers 
3-MC-type inducers are thought to bind to a 
cytosolic receptor that translocates into the nucleus and 
induces the synthesis of mRNA for a subset of P-450 
isozymes (53). PB-type inducers, on the other hand, are 
mediated by a less direct process. Ortiz de Montellano 
and Costa (54) suggest that a receptor exists for an 
endogenous substance that is specifically turned over by 
the trace amounts of P-450 present in the uninduced 
b 
liver. Changes in the concentration of this substance 
caused by the substances that inhibit P-450b would then 
trigger the induction response. PCBs are belived to 
display characteristics of both mechanisms. 
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Metabolism and Teratogenicity of 
Cyclophosphamide 
Activation of Cyclophosphamide 
Cyclophosphamide is one of the best studied 
teratogenic and antineoplastic agents (see 60 for a 
review). Activation of cyclophosphamide to its active 
teratogenic form is mediated by microsomal P-450 
monooxygenases in which carbon-4 of the ring is oxidized 
to form 4-hydroxycyclophosphamide. This initial 
metabolite subsequently undergoes ring opening to form 
the amino-aldehyde aldophosphamide such that 
4-hydroxycyclophosphamide is in equilibrium with the 
aldophosphamide. Two further metabolic fates are 
possible. One involves oxidation by soluble enzymes to 
yield 4-ketocyclophosphamide and carboxyphosphamide. 
This process constitutes the major detoxification pathway 
since neither of these two metabolites have cytotoxic 
activity and represent the major urinary excretory 
products of cyclophosphamide. The alternate pathway 
involves the spontaneous breakdown of 4-hydroxycyclo-
phosphamide/aldophosphamide to yield phosphoramide 
mustard and acrolein. Phosphoramide mustard is the 
metabolite believed to be responsible for the 
teratogenic/mutagenic effects of cyclophosphamide, 
however, acrolein may also play a role. 
17 
Target Molecules 
Cyclophosphamide belongs to a class of chemical 
mutagens known as alkylating agents. Alkylating agents, 
in general, and cyclophosphamide, specifically, are 
capable of alkylating a variety of macromolecules including 
DNA, RNA, and proteins. It is generally assumed, 
however, that DNA molecules constitute the critical 
target in terms of cytotoxicity. Several lines of 
evidence suggest this assumption. First, cytotoxic 
levels of cyclophosphamide inhibit DNA synthesis (61,62) 
and this inhibition seems to be due to damage of the DNA 
template (63-67). Second, DNA contains electron-rich 
targets for alkylation such as nitrogen and oxygen atoms 
of the nirogenous bases, as well as the phosphoryl 
oxygens and sugar-phosphate backbone, all of which have 
been shown to be alkylated by a variety of agents (68). 
Mehta et al. (69) have shown that phosphoramide mustard 
readily alkylates the N-7 position of guanosine and 
deoxyguanosine. Third, studies have shown that DNA 
cross-linking by bifunctional alkylating agents 
correlates with cytotoxicity and that drug-resistant 
cells do not exhibit cross-linked DNA. Finally, 
cyclophosphamide is also a carcinogen and a mutagen, and 
the critical target for· these processes is DNA. 
18 
Developmental Anomalies 
Cyclophosphamide primarily produces central nervous 
system and skeletal anomalies in rats, mice, rabbits, 
monkeys, and humans. Intraperitoneal injection of CP 
into Wistar and S/D rats produced fetuses characterized 
by brain malformations (anencephaly, exencephaly, and 
microencephaly), deformed palate and lip, open eyes, and 
defective limbs (retarded, club, ectrodactylic, 
syndactylic, and polydactylic) (70-72). Deformities 
reported in mice (73-74), rabbits (75), and monkeys (76) 
were similar to those found in rats and included kinky 
tail. The effects of metabolically activated CP on 
cultured whole rat embryos included abnormal brain 
development, hypoplasia of the mandibular arches, limb 
buds, and tail (77). Decreased growth was also 
noted (77). 
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ABSTRACT 
FETAX (Frog Embryo Teratogenesis Assay: Xenopus) is 
a 96 h teratogenesis screening assay using embryos of the 
South African clawed frog, Xenopus laevis. Since Xenopus 
embryos have limited xenobiotic metabolism through 96 
hours of development, we have developed an in vitro 
metabolic activation system employing Aroclor 1254 
induced rat liver microsomes. By adding an exogenous 
source of mixed functional oxidase (MFO) activity, we may 
more accurately assess the teratogenic risk of 
proteratogenic compounds. Xenopus embryos were 
cocultured with varying concentrations of 
cyclophosphamide (CP), Aroclor 1254 induced microsomal 
protein, NADPH generating system, and antibiotics in a 
static renewal fashion for 96 hours. Residual Aroclor 
1254 remaining in the microsomes was successfully reduced 
during purification to levels which had no significant 
effect on embryo survival and development. The results 
of three definitive dose-response tests performed with CP 
revealed that activation reduced the 96 h LC50 from 8.0 
to 1.4 mg/ml (5.7 fold). The 96 h EC50 (malformation) 
was reduced from 6.2 to 0.4 mg/ml (15.5 fold). 
Activation also increased the types and severity of 
malformation, and reduced embryonic growth. Aroclor 1254 
induced rat liver microsomes may be used as an acceptable 
in vitro metabolic activation system for FETAX. 
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proteratogen, Xenopus 
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INTRODUCTION 
Xenopus embryos have been used to determine the 
teratogenic and toxic effects of complex environmental 
mixtures and pure compounds (1-7). The Frog Embryo 
Teratogenesis Assay: Xenopus (FETAX) has been routinely 
used by several laboratories (8-13) since its development 
by Dumont and coworkers (7). 
In its present form, FETAX complies with most of the 
criteria required for in vitro teratogenesis assay 
validation (14). However, early Xenopus embryos have 
little or no ability to biotransform proteratogenic 
compounds to teratogenic metabolites via the microsomal 
mixed-functional oxidase system (MFO). Bantle and Dawson 
(15) recently have employed uninduced rat liver 
microsomes as an exogenous metabolic activation system 
for FETAX based on that of Kitchin and Woods (16) using 
cultured whole rat embryos. Such an activation system 
should increase the predictive accuracy of FETAX so that 
it can be used to detect human developmental toxicants. 
We have continued the development of an exogenous 
metabolic activation system for FETAX by using an Aroclor 
1254 induced rat liver microsomal activating/embryo 
coculture system with cyclophosphamide (CP). CP alone is 
neither antineoplastic nor mutagenic without metabolic 
activation (17). Since CP is one of the best studied 
proteratogens, it is an excellent candidate compound for 
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the development of such a system. Smith et al. (18) 
listed CP as a consensus compound for use in the 
validation of in vitro teratogenesis assays. 
This report describes the successful use of Aroclor 
1254 induced rat liver microsomes as an in vitro 
metabolic activation system for FETAX. A marked decrease 
in 96 h LC50 and EC50 (malformation) ~nd the 
identification of 4-hydroxycyclophosphamide/aldophosphamide 
(4-0HCP/AP), a cytochrome P-450 (P-450) catalyzed 
metabolite of CP, indicated that cyclophosphamide was 
successfully metabolized to its actively teratogenic 
forms. Standardizatidn of the P-450 content supplied to 
each CP treatment using aminopyrine N-demethylase 
activity as a basis allowed for repetitive dose-response 
curves. Less than 120 ng/ml residual Aroclor 1254 was 
present in the culture dishes. These concentrations did 
not affect Xenopus embryo development nor did they 
potentiate CP toxicity. The employment of an enhanced 
metabolic activation system protocol should greatly 
increase the predictive vilue and the overall acceptance 
of FETAX as an in vitro screening assay. 
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MATERIALS AND METHODS 
Chemicals and Biochemicals 
All chemicals used in rat liver microsome 
preparation and FETAX were purchased from Sigma (St. 
Louis, MO.). Reagents used in Aroclor 1254 analysis were 
purchased from Burdick and Jackson (Muskegon, MI.). 
Aroclor 1254 was obtained from Monsanto (St. Louis, MO.). 
Rat Liver Microsome Preparation 
Five days prior to microsome preparation, an adult 
Sprague-Dawley (S/D) C/D strain male rat (200-280 g) was 
injected with 500 mg/Kg Aroclor 1254 in corn oil (19). A 
modified procedure for microsomal isolation described by 
Kitchin and Woods (16) was followed. The liver was 
perfused with 50 ml of 1.15% KCl containing 0.02 M Tris-
HCl buffer, pH 7.5. Homogenization was performed in 
1.15% KCl containing 0.02 M Tris-HCl buffer and 0.5% 
bovine serum albumin (BSA). The homogenate was 
centrifuged successively at 600 and 9000 x g avg. The 
crude S-9 supernatant was further purified by two 
additional ultracentrifugation steps at 102,000 x g avg. 
The microsomal pellet was then resuspended in 0.05 M 
Tris-HCl buffer, pH 7.5, put into 1 ml aliquots, and 
immediately frozen in liquid nitrogen (20). Protein was 
determined by the method of Bradford (21) (BioRad, 
Richmond, CA). P-450 activity was inferred by the 
measurement of formaldehyde generated from the N-
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demethylation of aminopyrine by the method of Nash (22). 
Assay conditions were described by Lucier et al. (23). 
Several aliquots of microsomes were pretreated with 
carbon monoxide (CO) to selectively inactivate P-450 
activity (15). 
Animal Care and Breeding 
Xenopus adult care, breeding, and embryo collection 
was performed according to Courchesne and Bantle (8). 
Assay Protocol 
Initial tests were conducted to optimize the 
cytochrome P-450 activity and determine the most suitable 
concentration of microsomal protein, NADPH generating 
system, and antibiotics using sublethal and 
subteratogenic levels of unactivated CP. For each 
separate clutch of embryos, four sets of 20 were placed 
in 60 mm covered plastic Petri dishes containing FETAX 
solution and 100 U/ml penicillin-100 ug/ml streptomycin 
in 8 ml of total solution. These were designated FETAX 
controls. Treatments were performed in duplicate with 20 
embryos per dish. Each test dish received microsomal 
protein, NADPH generating system, 100 U/ml penicillin-100 
ug/ml streptomycin, and various concentrations of CP. 
The NADPH generating system consisted of 3.5 mM glucose 
6-phosphate, 0.31 U/ml glucose 6-phosphate dehydrogenase, 
0.1 mM NADP, and 0.007 mM NADPH. Metabolic activation 
system, unactivated CP controls, and CO-gas~d microsomes 
controls were prepared in a similar manner. All dishes 
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contained 8 ml of the appropriate solutions, which were 
previously diluted from stocks prepared in FETAX 
solution. All solutions were removed every 24 h of the 
four d test and fresh solutions added in a static-renewal 
fashion. 
Data Collection and Analysis 
Dead embryos were removed every 24 h and the number 
recorded. Death at 24 and 48 h was ascertained by embryo 
skin pigmentation, structural integrity, and 
irritability. At 72 and 96 h the lack of a heart beat 
was an unambiguous sign of death in the transparent 
embryo. Surviving larvae were fixed in 0.6% formalin, pH 
7.0. The number of live-malformed embryos and the stage 
of development according to Nieuwkoop and Faber (24) were 
determined. Dose-response bioassays evaluated according 
to Litchfield-Wilcoxon (25) were used to determine the 96 
h LC50 and EC50 (malformation). The 96 h LC50 was 
divided by the EC50 (malformation) yielding a 
teratogenicity index (TI) which has proven useful in 
assessing teratogenic risk (7,12). Head-tail length was 
measured using a Radio Shack digitizer and model 16 
microcomputer. 
Detection of Residual Aroclor 1254 
Residual Aroclor 1254 remaining in the microsomal 
fraction was determined by gas-liquid chromatography 
(GLC) in accordance with standard methods (26). Three 
successive methylene chloride extractions were performed 
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on samples of purified microsomes. 1 ml of isooctane 
was added and the samples concentrated to 500 ul in a 
tube heater. Analysis of the extracts was performed with 
a Tracor model 560 gas chromatograph operated under the 
following conditions: 
Column: 5% OV-1 on 80/100 Supelcoport (Supelco, 
Bellefonte, Pa) 6' x 0.25'' ID glass packed 
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Detector: Ni Electron Capture 
Carrier Gas: Argon-Methane (95%:5%) flowing 45 ml/min 
0 
Temperatures ( C): Oven-250 
Injection Port-255 
Detector-240 
Integratator: Hewlett Packard model 3390A 
Sample peak retention times were compared to Aroclor 
1254 reference standards. Identification of Aroclor 1254 
was determined by the presence of five major peaks. 
Three differing concentrations of Aroclor 1254 standards 
were analyzed in triplicate. Samples were analyzed in 
duplicate. Environmental Protection Agency (EPA) quality 
control standards were performed to confirm the accuracy 
of quantification. Concentration of Aroclor 1254 in 
extracts was computed by regression analysis. Efficiency 
of extraction was determined by spiking uninduced 
microsomal preparations with known quantities of Aroclor 
1254. 
Detection of CP Metabolism 
Qualitative analysis of CP metabolism was determined 
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by GLC. The following treatments were prepared in Petri 
0 
dishes and incubated at 24 C similar to those subjected 
to the embryos: 4.0 mg/ml CP, MAS control, CO-gassed MAS 
and 4.0 mg/ml CP, and 4.0 mg/ml induced microsome 
activated CP. At 0, 0.5, 3, 6, and 24 h the incubations 
were stirred, a sample removed, and immediately injected 
onto a Tenax GC (60/80) 6' x 0.25'' ID glass packed 
column (Applied Science Laboratory, State College, Pa.) 
under the following conditions: 
Detector: Flame Ionization Detector 
Carrier Gas: Helium flowing 22 ml/min 
Air flow: 400 ml/min 
Hydrogen gas flow: 20 ml/min 
0 
Temperatures ( C): Oven-200 
Injection Port-240 
Detector-250 
Retention times of the samples relative to the water 
solvent were then compared to a 4-00HCP standard which 
spontaneously hydrolyzed to 4-0HCP, the primary 
metabolite of CP. No quantitative assessment was sought. 
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RESULTS 
Optimization of the Metabolic Activation System 
Preliminary optimization experiments were conducted 
to maximize CP bioactivation without increasing the 
metabolic activation system components to toxic levels. 
Tests were performed to determine the optimum 
concentration of aminopyrine N-demethylase (APD) activity 
added to each CP treatment. The optimum level of APD 
activity was determined to be 0.04 U/ml which caused 
signigicant malformation, but only moderate mortality. 
Subsequent dose-response tests received 0.04 U/ml APD. 
No further adjustments in the NADPH generating system or 
antibiotics were found necessary from that previously 
described (15). The concentration of induced microsomal 
protein which caused a (5% reduction in growth was 
defined as the maximum which could be subjected to the 
embryos. Figure 1 shows that under these constraints, 
the induced microsomal protein content of each co-culture 
could not exceed 0.06 mg/ml. 
Effect of Bioactivation on CP Toxicity and Teratogenicity 
The effect of metabolic activation on CP toxicity 
and teratogenicity is presented in Figure 2. Activation 
reduced the 96 h LC50 5.7 fold from 8.0 to 1.4 mg/ml. 
The 96 h EC50 (malformation) was reduced 15.5 fold from 
6.2 to 0.4 mg/ml. The 96 hour TI was increased 2.7 fold 
upon activation from 1.3 to 3.5. The malformations 
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observed in unactivated CP at concentration (7.0 mg/ml 
were generally slight to moderate skeletal disorders, 
edema, and improper gut coiling. At unactivated CP 
concentrations greater than 7.0 mg/ml moderate to severe 
skeletal kinking, edema, and improper gut coiling 
occurred. Activation increased both the number of 
different types and severity of malformation. Severe 
skeletal disorders, head and eye malformations, edema, 
and impairment of gut coiling were characteristic 
malformations found with activated CP (Figure 3). Table 
I shows that carbon monoxide treatment of induced 
microsomes successfully inactivated P-450, indicated by 
the marked increase in embryo survival and normal 
development in the presence of 4.0 mg/ml CP. All embryos 
exposed to 4.0 mg/ml normally activated CP died. 
Success of Cytochrome P-450 Standardization 
To determine the success of P-450 standardization, 
three dose-response assays were performed, each with a 
different clutch of embryos (Table I). The repetitive 
nature of the results and generally narrow confidence 
limits indicate that P-450 content had been successfully 
standardized by the measurement of APD activity. 
Effect of Activation on Embryo Growth 
The effect of CP activation on embryo growth is 
represented in Figure 4. The reduction in growth of 
those embryos exposed to activated CP occurred at 
markedly lower concentrations than those exposed to 
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unactivated CP. The growth reduction (% of control 
growth) observed in embryos exposed to 0.5 mg/ml 
activated CP was similar to the effect observed in 6.0 
mg/ml unactivated CP. Embryos exposed to 4.0 mg/ml CP 
plus CO-gassed microsomes, and 4.0 mg/ml unactivated CP 
were 90.6 and 95.5% of control growth, respectively. 
Effect of Residual Aroclor 1254 
The effect on embryo development and growth of 
residual Aroclor 1254 remaining in the microsomal 
preparation is shown in Table II. The Aroclor 1254 
extraction efficiency was estimated to be approximately 
70%. Addition of 0.5% BSA to the liver homogenization 
buffer reduced the Aroclor 1254 concentration from 21.2 
to 6.2 ug/ml. Each Petri dish was estimated to contain 
from 30 to 120 ng/ml Aroclor 1254 depending on the amount 
of added microsomal protein. Whole e•bryo exposure to 
Aroclor 1254 spiked microsomal protein indicated that 
this range had little adverse effect on embryonic 
development and growth. A single experiment revealed 
that the 96 h lethal lowest observable effect 
concentration (LOEC) for CP activated by both uninduced 
microsomes and uninduced microsomes spiked with 1 ug 
Aroclor 1254 was 1.0 mg/ml. Additionally, the embryo-
lethal effect generated by 2 and 3 mg/ml CP activated by 
uninduced and Aroclor 1254 spiked uninduced microsomes 
was consistent. Therefore, the residual Aroclor 1254 
appeared not to potentiate CP nor did interaction appear 
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to affect toxicity and teratogenicity. 
Identification of Metabolites 
Table III lists the absolute retention times from 
the GLC analysis of bioactivated CP. The 2.58, 5.58, 
5.71; and 3.61, 6.81, 10.16, 15.42 min peaks corresponded 
to the CP and metabolic activation system (MAS), 
respectively. The 9.06 min peak present in the 4-00H CP 
standard was also present in the metabolically activated 
CP sample, but absent in each of the other treatments. 
Since 4-00HCP spontaneously hydrolyzed to 4-0HCP, the 
MFO-derived metabolite of CP, we believe that this peak 
was the result of CP metabolism. Detectable quantities 
of 4-0HCP/AP were not present until 30 min, but were 
detected throughout the remainder of the 24 h assay. The 
lack of a 9.06 min peak in the CO-gassed MAS and 4.0 
mg/ml CP culture gave further indication that the carbon 
monoxide treatment preferentially inactivated P-450. 
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DISCUSSION 
The results of this study indicate that the Aroclor 
1254 induced rat liver microsome metabolic activation 
system successfully bioactivated CP into highly toxic and 
teratogenic species. The greater than 2.5 fold increase 
in the TI upon activation suggests that metabolism has a 
greater effect on the teratogenicity than the toxicity of 
the active metabolites. We consider nonteratogens to be 
those compounds that have TI values (1.5. As teratogenic 
risk increases, the TI rises to )1.5. CP was not 
teratogenic (TI=l.3)· unless it was metabolically 
activated, whereupon it became a strong teratogen 
(TI=3.5). The decrease in line slope found with 
bioactivated CP further indicates that the range of 
teratogenic concentrations increases as well. Bantle and 
Dawson (15) reported a TI value of 1.4 for activated CP 
using uninduced microsomes, 2.5 fold less than we report 
with Aroclor 1254 induced microsomes. The detection of 
4-0HCP in the activated CP cultures and the greater TI 
value seem to indicate that the enhanced system more 
effectively converted CP into active teratogenic 
metabolites. The induction of the proper P-450 isozymes 
required for CP bioactivation may account for the greater 
developmental toxicity we achieved. Although the TI may 
not always indicate whether a compound is a teratogen, 
the severity of the malformation produced was a strong 
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indication that activated CP was teratogenic. The rate 
of growth inhibition and overall reduction in growth 
increased with bioactivation and the subsequent increase 
in teratogenicity. This trend was consistent with 
findings of Dawson and Bantle (12) for ethanol, 
saccharin, caffeine, and 5-fluorouracil. 
The malformations observed Xenopus embryos due to 
activated CP exposure appear similar to those recorded in 
mammalian studies. Intraperitoneal injection of CP into 
Wistar and S/D rats produced fetuses characterized by 
brain malformations (anencephaly, exencephaly, and 
microencephaly), deformed palate and lip, open eyes, and 
defective limbs (retarded, club, ectrodactyly, 
syndactyly, and polydactyly) (27-29). Deformities 
reported in mice (30-31), rabbits (32), and monkeys (33) 
were similar to those found in rats and included kinky 
tail. The effects of metabolically activated CP on 
cultured whole rat embryos included abnormal brain 
development, hypoplasia of the mandibular arches, limb 
buds, and tail (34-35). Decreased growth was also 
noted (35). 
Anomalies in Xenopus as the result of activated CP 
exposure were severe to moderate head malformations 
(microencephaly and anencephaly), opthalmic 
abnormalities, impairment of gut coiling, and severe 
skeletal kinking. Embryo growth also was significantly 
impaired. Since FETAX is a 96 h test, it is incapable of 
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detecting limb malformations. Skeletal kinking observed 
in Xenopus may bear some relationship to the skeletal 
limb defects observed in mammals. Dawson and Bantle (12) 
have observed the same relationship with ethanol (36), 
caffeine (37-38), and 5-fluorouracil (39-40). 
The use of BSA in the liver homogenization buffer 
and additional purification by ultracentrifugation 
reduced the residual Aroclor 1254 concentration to 
acceptable levels. Initial attempts to employ 
commercially available Aroclor 1254 induced rat liver S-9 
supernatant (Litton Bionetics) failed due to high 
toxicity thereby prompting this investigation of the use 
of purified microsomes. In future validation work 
Aroclor 1254-toxicant potentiation and interaction will 
need to be closely investigated. An additional method of 
reducing residual Aroclor 1254 would be to use only those 
congeners responsible for P-450 induction. We are 
actively pursuing this possibility. 
Aroclor 1254 induction may present one primary 
disadvantage. Aroclor 1254 has been thought to reduce 
the amount of particular P-450 isozymes in the liver as 
was suggested with thalidomide (41). However, Aroclor 
1254 induced microsomes offer several advantages over 
uninduced preparations. The deleterious background 
effects of the microsomal activation system must be 
minimal. This was not the case with the uninduced 
microsomal protein/Xenopus embryo coculture system. 
36 
Bantle and Dawson (15) pointed out that much of the 
reduction in Xenopus growth observed in the activated CP 
treatments was due to the uninduced metabolic activation 
system itself. By using induced microsomes, less than 
half of the uninduced protein originally required was 
necessary to achieve CP activation. To achieve similar 
assay data, Bantle and Dawson (15) were required to use 
0.1-0.12 mg/ml of uninduced microsomal protein. This 
level retarded embryo growth to 8% of the control. In 
the present study, the growth inhibiting effect of the 
Aroclor 1254 induced metabolic activation system 
including bacterial contamination was reduced to (5%. 
The effects generated by induced microsomal protein were 
mainly the result of bioactivation and not the metabolic 
activation system itself. 
The evaluation of P-450 content by measuring APD 
activity is rapid and inexpensive. Differential 
spectrophotometry used previously (15,42) is tedious and 
often compromised by sample turbidity. The repetitive 
results obtained in this study give a fair indication 
that P-450 was successfully standardized. However, for 
each validation compound tested in the future the success 
of standardization will need to be evaluated in a similar 
manner. 
The large number of new chemicals manufactured and 
released each year, many of which pose a human health 
risk, warrants the use of short-term in vitro 
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teratogenesis screening assays such as FETAX. Without 
metabolic capabilities, the success of these assays as 
screens for human developmental toxicants is doubtful. 
Proteratogenic compounds that evade detection may be 
converted to teratogenic forms in humans and cause birth 
defects. Biotransformation of proteratogenic compounds 
is a recognized obstacle in most in vitro assay systems, 
but must not be overlooked in a proper teratogenesis 
screening test (14). We are presently conducting further 
validation work with a variety of direct-acting and 
proteratogenic compounds. By employing Aroclor 1254 
induced rat liver microsomes as a metabolic ~ctivation 
system for FETAX the number of false negative and 
positive results may be minimized. 
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Table I. Effect of Activated CP on Xenopus Embryo Mortality and 
Malformation. 
Treatment 
FETAX Solution 
Mortality 
(%) 
Malformation 
(%) 
(w/Pen-Strep) 0 1.3 
Metabolic Activation 0 4.2 
System 
CO-gassed Metabolic 
Activation System 
1 
and 4.0 mg/ml CP 0.8 14.3 
1 
Activated CP : 
1 
2 
3 
1 
Cyclophosphamide 
LC50 
(mg/ml) 
1.36 
(0.78-2.33) 
1.29 
(1.08-1.54) 
1.46 
(1.26-1.39) 
EC50 
(mg/ml) 
0.44 
(0 .12-1.64) 
0.33 
(0.11-1.11) 
0.39 
(0.29-0.53) 
TI 
3.1 
3.9 
3.7 
Results from three 96 h tests in which 80 embryos were exposed to FETAX 
solution and 40 exposed to each additional treatment. 96 h LC50 and EC50 
(malformation) values presented with respective 95% confidence limits 
were determined by the Litchfield-Wilcoxon test. The Teratogenicity 
Index (TI)=96 h LC50/96 h EC50 (malformation). 
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Table II. Effect of Residual Aroclor 1254 in the Rat Liver Metabolic 
Activation System on 96 h Xenopus Embryo Mortality, 
Malformation, and Growth. 
Treatment Microsomal Aroclor 1254 Mortality Malformation Growth 
protein spike 
(mg/ml) (ug/ml) (%) (%) (% of 
control) 
Control 
(w/Pen-Step) 2.5 7.7 
Uninduced 
Metabolic 
Activation 
System 0.1 10.0 11.1 98.9* 
Aroclor 
Spiked 
Metabolic 
Activation 
System 0.1 0.26 7.5 10.6 97.2* 
0.1 0.18 10.0 16.7 96.6* 
0.1 0.13 5.0 10.5 97.0* 
0.1 0.05 2.5 5.1 97.8* 
0.1 0.02 0 5.0 100.4* 
0.1 0.01 0 5.0 99.6* 
*Not significant (P=0.05, Student's t-test). 
Results from a 96 h test in which embryos were subjected to varying 
concentrations of Aroclor 1254 spiked into an uninduced metabolic 
activation system. 80 embryos were designated controls and 40 
embryos were subjected to each particular treatment. 
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Table III. Qualitative Analysis of 4-Hydroxycyclophosphamide in 
Metabolically Activated CP Cultures using GLC. 
Absolute Retention 
Time 
(min) 
1 2 
MAS CP Activated 
3 
CP 
Oh 0.5h 1h 3h 6h 24h 
1.27 
2.58 + 
3.12 
3.61 + 
5.58 + 
5.71 + 
6.81 + 
9.06 
10.16 + 
15.42 + 
27.54 
1 
Metabolic activation system 
2 
Cyclophosphamide (CP) 
3 
+ + + + + + 
+ + + + + + 
+ + + + + + 
+ + + + + + 
+ + + + + 
+ + + + + + 
+ + + + + 
Metabolically activated cyclophosphamide 
4 
4-Hydroperoxycyclophosphamide 
5 
4 
4-00HCP 
+ 
+ 
+ 
+ 
Carbon monoxide gassed metabolic activation system and CP 
CO-MAS 
5 
& CP 
+ 
+ 
+ 
+ 
Results from GLC analysis in which various cultures were analyzed for 
the presence of 4-0HCP. Retention times are relative to water solvent. 
(+) indicates the presence of a particular peak and (-) the absence. 
Sample peaks were compared to a 10 mg/ml 4-00HCP standard. The 
activated CP culture contained the induced MAS and 4.0 mg/ml CP. 
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FIGURE LEGENDS 
Figure 1 - Effect of increasing protein concentration on 
96 h Xenopus embryo growth. All other 
components of the MAS were as described in 
Methods and Materials. 
Figure 2 - Dose-Response curves for Xenopus embryos 
exposed to activated CP (mg/ml) ( •) mortality, 
(A) malformation; and unactivated CP (mg/ml) 
( [J) mortality, ( & ) malformation after 96 h 
exposure. 
Figure 3 - Malformations and growth reduction caused by 
96 h exposure to activated CP. Control embryo 
(top) and Xenopus embryo exposed to 
3.0 mg/ml microsomal activated CP (bottom). 
Figure 4 - Representative Xenopus embryo growth curves 
for 96 h exposure to <•) activated and (A) 
unactivated CP (mg/ml). 
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